Immunology Platform 2012

Size: px
Start display at page:

Download "Immunology Platform 2012"

Transcription

1 Immunology Platform 2012 The scientific activity report of Immunology Platform of the Institut Pasteur du Cambodge for the period January 1st to December 31st, Scientific activity report Prepared by: Polidy Pean, Head, Immunology Platform Institut Pasteur du Cambodge, 5, Bvd. Monivong BP Phnom Penh, Royaume du Cambodge

2 Research team Team leader: Polidy Pean, MD, PhD Technical staff : Ratana Meng Annual Report ANRS sites in Cambodia Introduction Cambodia is one of the countries with the highest prevalence of HIV and tuberculosis (TB) infections. An estimation of 64% and 0.7% Cambodian people were infected by TB and HIV-1 respectively, and HIV-1/TB co-infection has increased annually, from 2.5% in 1995 to 10% in The effective treatments of both infections have reduced the mortality and morbidity. However, simultaneous treatments of both infections were complicated by many problems such as drug toxicity, drug resistance and tuberculosis associated immune reconstitution inflammatory syndrome (TB-IRIS). TB-IRIS occurs in 10 to 25% of patients who were treated with antiretroviral and anti tubercular drugs. It could be an obstacle for antiretroviral therapy management and may have an impact on immune reconstitution in severely immunocompromized patients. Diagnosis of TB-IRIS is very difficult and is always a clinical diagnosis of exclusion. Thus, the understanding of mechanism of TB-IRIS, the impact of TB-IRIS on immune reconstitution and identification of its related biomarkers for prediction and diagnosis of this syndrome is very important. Research Activities in ANRS project: Camelia Paradoxical Reaction Immune NK cells study (CAPRI-NK) Principal Investigators: Dr Daniel Scott-Algara (IP Paris) and Dr Eric Nerrienet (IP Cambodia) Partners: CAMELIA Operational Team and CAMELIA clinical investigators) In collaboration with Dr Daniel Scott Algara and his colleagues (Pasteur Institute in Paris) and CAMELIA (Cambodian Early versus Late Introduction of Antiretroviral Drugs) clinical trial team and with the grant support from ANRS 12153, we investigated the implication of innate immunity of NK cells in the onset of IRIS in HIVinfected patients with TB to identify predictive markers of IRIS. As the results, 128 HIV-infected patients with TB from the CAMELIA trial were enrolled in the study. Thirty-seven of the 128 patients developed IRIS. At inclusion, patients had low CD4 cell counts (27cells/mm3) and high plasma viral load (5.76 and 5.50 log/ml in IRIS and non-iris patients, respectively). At baseline, NK-cell degranulation capacity was significantly higher in 2 P a g e

3 IRIS patients than in non-iris patients (9.6% vs 6.38%, P <0.005). At IRIS onset, degranulation capacity did not differ between patients, whereas activating receptor expression was lower in IRIS patients. Patients with degranulation levels > 10.84% had a higher risk of IRIS (P = by log-rank test). Degranulation level at baseline was the most important IRIS predictor (hazard ratio = 4.41; 95% confidence interval, ). These results have been published in Blood on april We also investigated NK cell reconstitution in HIV/TB co-infection (IRIS and non-iris patients) at 8 weeks of cart in comparison with HIV mono-infected patients at 6 weeks of cart. As result, we found that NK cell degranulation was similar in TB-IRIS and non TB-IRIS patients following early cart (6 weeks). A trend towards a decrease of total degranulation capacity from baseline to 6 weeks of cart was observed in TB-IRIS and a slightly increase in non TB-IRIS when they were compared to baseline value. By contrast, the total degranulation capacity of NK cell was significantly increased in HIV mono infected patients at 8 weeks of cart (p< 0.001). When delta values of total degranulation were compared, significant differences were found between HIV mono infected patients and IRIS and non IRIS patients (p=0.004 and p<0.001, respectively). We did not detect any increase of the total IFN- secretion by NK cell after target stimulation after 6 weeks of cart in TB/HIV co-infected patients and this is in contrast to those observed in HIV infection alone. In addition, the evolution of CD107a + IFN- + NK cells from baseline to 6/8 weeks of cart has also been found to be low in both TB-IRIS and non-tb-iris group, whereas those in HIV treated patients was increased. Globally, we did not find any difference in term of evolution of NK cell degranulation activity and/or IFN- secretion between TB-IRIS and non TB-IRIS patients during the follow up. A manuscript of those results is in preparation. Research Achievements and Outcomes. Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood; 119(14): Training: One Cambodian PhD student ( Mr Pean Polidy) has successfully defended his thesis on this project in December P a g e

4 ANRS project Camelia Paradoxical Reaction Immune T cells study (CAPRI-T) Principal investigators: Pr Anne Goldfed ( Boston USA), Dr Pean Polidy ( IP Cambodia) Partners: CAMELIA operational team, Camelia clinical investigators, CHC This study is supported by ANRS and US NIH (for a supplemented grant). In collaboration with Professor Anne Goldfeld s team (Program in Cellular and Molecular Medicine, Children s Hospital-Boston, USA) and CAMELIA clinical trial team, we investigated the immunological basis of TB-IRIS in patients enrolled in CAMELIA clinical trial and its impact on T cell reconstitution. Our aim is to examine the evolution of T cell compartment in TB/HIV co-infected patients (CD4+ T cell counts <200/mm3) enrolled in the trial. We compared the results from patients who developed TB-IRIS within 3 weeks after initiating cart to those who did not develop TB-IRIS (non TB-IRIS). Whole blood T cells immunophenotypes and serum cytokines from 36 TB-IRIS and 104 non-tb- IRIS patients were evaluated prior to ART and at timepoints up to 32 weeks post-art initiation. As the result, in patients who developed TB-IRIS there were significantly higher proportions of activated HLA-DR+CD4+ (p=0.005) and CCR5+CD4+ (p<0.0001) T cells. There were similar levels of activated CD38+CD8+ and regulatory CD4+ T (CD25+/CD127lo) cells in the two groups at cart initiation and at ensuing timepoints. While CD62L- CD45RA- CD4+ effector memory (EM) T cell proportions continued to increase after the TB-IRIS event up to week 32, while in non TB-IRIS patients CD4+EM cell reconstitution stabilized by week 8 post-art (p=0.005). Within the first two weeks post-art, HLA-DR+CD4+ (p=0.0023) and CCR5+CD4+ (p=0.0035) T cell proportions, and serum levels of IL-1 (p=0.026) and IL-6 (p=0.0066), increased at significantly faster rates in TB-IRIS patients as compared to non TB-IRIS patients. In conclusion, global CD4+ T cell activation, elevated CCR5+CD4+ T cell levels and viral load were significantly higher at ART initiation in TB-IRIS patients. The increase in IL-1 and IL-6 after ART initiation in TB-IRIS patients with increased viral antigen load may drive the elevated CD4+ T cell activation in TB-IRIS patient. Research Achievements and Outcomes. Scientific communication: an abstract on Impact of Tuberculosis-Associated IRIS on T Cell Activation and Reconstitution in Highly Immunosuppressed HIV/TB Co-Infected Patients Starting ART has accepted for discussion and poster presentation in 20 th CROI 2013 (US-Atalanta). (Abstract No S-186) Publication: The manuscript of this result is in preparation. Training: One Cambodian PhD student (Mr Pean Polidy) has successfully defended his thesis on this project on december P a g e

5 ANRS Study: Improving diagnosis of Tuberculosis in HIV infected children in Asia (Cambodia, Vietnam) and in Africa (Burkina Faso, Cameroon) (PAANTHER 01) Principal investigators: Dr Olivier Marcy (France), Dr Ung Vibol (Cambodia. Regional Project Manager: Dr Laurence Borand - Country project Manager: Mrs Pheng Phearavin Collaborators: National Pediatric hospital (Phnom Penh) and Angkor Hospital for Children (Siem Reap), Epidemiology and Public Health Unit, Clinical laboratory Unit, Immunology Platform IP Cambodia Childhood tuberculosis (TB) accounts for 11% of the total 9 million annual TB cases and is still not considered a public health priority in endemic countries. The difficulty of diagnosing TB in children is increased in case of HIV infection, in a situation of very high morbidity and mortality and major therapeutic and care issues. The tests currently available in developing countries as well as diagnostic approaches recommended by the national programs or WHO are not sufficiently sensitive and specific. Improved diagnostic criteria are imperative. The new immunological tests measuring the secretion of interferon-gamma (IGRAs) by lymphocytes activated by specific Mycobacterium tuberculosis (MTB) complex antigens are interesting alternatives to the tuberculin skin test (TST), but must be evaluated in immunocompromised children. Our aims is to evaluates the sensitivity, specificity, positive and negative predictive values of an in-vitro Interferon Gamma Release (IGRAs): the QuantiFERON -TB Gold In-Tube, for the diagnosis of TB in HIV infected children and to compare the performances of two in-vitro IGRAs: the QuantiFERON -TB Gold In-Tube and the T.SPOT- TB, for the diagnosis of tuberculosis in HIV infected children in a sub-group of children (in Cambodia). This multicentric study is done in collaboration with Dr Nguyen Thi Ngoc Lan team (Microbiology Laboratory, Pham Ngoc Thach Hospital, Ho Chi Minh City Vietnam), Dr Guislaine Carcelain (Hôpital Pitié-Salpêtrière, Paris, France) and Epidemiology and Public Health Unit of IPC (Dr Laurence Borand) and with grant support from ANRS On November 30 th, 2012, 84/120 suspected HIV/TB coinfected children were enrolled in Cambodia. The inclusion and data collection are ongoing. 5 P a g e

6 Perspective: Participation of the Platform of Immunology (Dr PEAN Polidy) and the HIV/Hepatitis Unit (Mr NOUHIN Janin) Impact of maternal HIV infection and feeding mode on the maturation of innate immunity and morbidity in infants in the context of the elimination of MTCT* of HIV-1 in Cambodia (CAMENI) See Report NOUHIN Janin Scientific production Publication: Pean P, Nerrienet E, Madec Y, et al. Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis. Blood; 119(14): Scientific communication: an abstract on Impact of Tuberculosis-Associated IRIS on T Cell Activation and Reconstitution in Highly Immunosuppressed HIV/TB Co-Infected Patients Starting ART has accepted for discussion and poster presentation in 20 th CROI 2013 (US-Atalanta). (Abstract No S-186) 6 P a g e

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011 Guidelines for TB Blood Testing Minnesota Department of Health TB Prevention and Control Program June 2011 Outline Interferon-Gamma Release Assays aka TB blood tests 1. What are they? 2. What are the current

More information

TB diagnostics in western and poor countries suggestions for progress

TB diagnostics in western and poor countries suggestions for progress TB diagnostics in western and poor countries suggestions for progress George Janossy (Royal Free, emeritus professor) in collaboration with Drs. Marc Lipman, Simon Barry, Ronan Breen, Tim McHugh et al.

More information

Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB

Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB Incidencia y Características Clínicas del Síndrome Inflamatorio de Reconstitución Inmune (IRIS) en el Contexto de la Coinfección VIH-TB Dr. Christian Manzardo Hospital Clínic/IDIBAPS- Universidad de Barcelona

More information

What is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives

What is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives What is an IGRA? Are they available here? How do I use them? Debbie Staley, RN, MPH TB Nurse Consultant VDH Division of Disease Prevention TB Control Program Learning Objectives Participants will be able

More information

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0 Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharan

More information

Lisa Y. Armitige, MD, PhD has the following disclosures to make:

Lisa Y. Armitige, MD, PhD has the following disclosures to make: Interferon Gamma Release Assays (IGRAs) Lisa Y. Armitige, MD, PhD May 13, 2015 TB for Pulmonologist Phoenix, AZ March 13, 2015 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following

More information

CDC TB Testing Guidelines and Recent Literature Update

CDC TB Testing Guidelines and Recent Literature Update Pocket Guide QuantiFERON -TB Gold CDC TB Testing Guidelines and Recent Literature Update Using IGRAs for TB screening in your patients June 2010 A full copy of the US Centers for Disease Control and Prevention

More information

Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB)

Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB) Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB) Draft Interim HPA Guidance HPA Tuberculosis Programme Board Health Protection

More information

DRAFT FOR CONSULTATION

DRAFT FOR CONSULTATION Interferon Gamma Release Assay (IGRA) testing for tuberculosis (TB) - Questions & Answers (Q&As) For Health Care Workers HPA Tuberculosis Programme Board DRAFT FOR CONSULTATION October 2007 Interferon

More information

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is

More information

TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016

TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016 TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646

More information

Tuberculosis in children in Europe -the ptbnet

Tuberculosis in children in Europe -the ptbnet Tuberculosis in children in Europe -the ptbnet Beate Kampmann FRCPCH PhD A/Professor in Paediatric Infection & Immunity Consultant Paediatrician Imperial College London, UK and Institute of Infectious

More information

Journal of Infectious Diseases Advance Access published January 26, 2015

Journal of Infectious Diseases Advance Access published January 26, 2015 Journal of Infectious Diseases Advance Access published January 26, 2015 1 Effect of immune status on serial QuantiFERON-TB Gold In-Tube LTBI screening in persons with HIV in a low TB incidence country

More information

CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial

CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial CYP2B6 and NAT2 genetic polymorphisms enlighten the pharmacokinetic interaction of efavirenz with rifampicin and isoniazid - ANRS 12154 trial Julie Bertrand 1,2, Céline Verstuyft 3,4, Monidarin Chou 5,

More information

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology

More information

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive San Antonio, Texas November 11 14, 2014 TB Intensive San Antonio, Texas November 11 14, 2014 TB in the HIV Patient Lisa Armitige, MD, PhD November 13, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests

More information

Pediatric Latent TB Diagnosis and Treatment

Pediatric Latent TB Diagnosis and Treatment Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children

More information

Pregnancy and Tuberculosis. Information for clinicians

Pregnancy and Tuberculosis. Information for clinicians Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB

More information

Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention

Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention Screening Infants and Children for Tuberculosis in Massachusetts Executive Summary In Massachusetts,

More information

Childhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine

Childhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine Childhood Tuberculosis Some Basic Issues Jeffrey R. Starke, M.D. Baylor College of Medicine TUBERCULOSIS IS A SOCIAL DISEASE WITH MEDICAL IMPLICATIONS THE GREAT PARADOX OF TUBERCULOSIS A CAUTIONARY TALE

More information

IGRAs in Children. Deborah Anne Lewinsohn, MD. Associate Professor Infectious Disease, Pediatrics

IGRAs in Children. Deborah Anne Lewinsohn, MD. Associate Professor Infectious Disease, Pediatrics IGRAs in Children Deborah Anne Lewinsohn, MD Associate Professor Infectious Disease, Pediatrics Disclosure Statement: Deborah Lewinsohn I have no significant financial interests in Cellestis or Oxford

More information

Challenges of TB in the HIVinfected. CORE Group SOTA Douglas Watson, M.D. University of Maryland, Baltimore 6 October 2009

Challenges of TB in the HIVinfected. CORE Group SOTA Douglas Watson, M.D. University of Maryland, Baltimore 6 October 2009 Challenges of TB in the HIVinfected child CORE Group SOTA Douglas Watson, M.D. University of Maryland, Baltimore 6 October 2009 Challenges of TB in the HIVinfected child Epidemiology: Common, but incidence

More information

IGRA Use in a Local Public Health Setting

IGRA Use in a Local Public Health Setting IGRA Use in a Local Public Health Setting LAURIE HICKSTEIN, RN, BSN SENIOR PUBLIC HEALTH NURSE HALEY BLAKE DISEASE INVESTIGATION AND INTERVENTION SPECIALIST Disclaimer We have done no research for companies

More information

Pathogens and the immune system

Pathogens and the immune system Review of lecture 7 Pathogens and the immune system Veronica Leautaud, Ph.D. vl2@ rice.edu BRC 511 / 530-lab Lecture 8 BIOE 301-Bioengineering and World Health Science Science is the human activity of

More information

Module 3 TREATMENT OF CHILDHOOD TB

Module 3 TREATMENT OF CHILDHOOD TB Module 3 TREATMENT OF CHILDHOOD TB Burden of TB in children Tuberculosis (TB) in children is common wherever TB is common in adults i.e. TB endemic settings TB is an important cause of illness and death

More information

Targeted Testing for Tuberculosis Infection

Targeted Testing for Tuberculosis Infection Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for

More information

Nevada State Health Division Technical Bulletin

Nevada State Health Division Technical Bulletin Nevada State Health Division Technical Bulletin Topic: Using QuantiFERON and Tuberculin Skin Test to Screen for TB Section/Program/Contact: Bureau of Community Health / Tuberculosis Program / Susanne Paulson,

More information

Diagnosis of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

Diagnosis of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Diagnosis of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has

More information

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Antiretroviral therapy for HIV infection in infants and children: Towards universal access Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous

More information

QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company

QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company QuantiFERON TB Gold In Tube Method (QGIT Test) Manufacturer: Cellestis Inc. (USA) a QIAGEN Company P1078 TB APPRISE TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed

More information

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die

More information

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System

Asthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System 1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID

More information

Guidelines for Using the QuantiFERON -TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection

Guidelines for Using the QuantiFERON -TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection Recommendations and Reports January 31, 2003 / 52(RR02);15-18 Guidelines for Using the QuantiFERON -TB Test for Diagnosing Latent Mycobacterium tuberculosis Infection Prepared by Gerald H. Mazurek, M.D.

More information

Interferon-gamma Release Assays: the Good, the Bad, and the Ugly

Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Interferon-gamma Release Assays: the Good, the Bad, and the Ugly Susan E. Dorman, MD Center for TB Research Johns Hopkins University School of Medicine Maryland Center for Tuberculosis Control and Prevention

More information

International Infectious Disease Research and Mentoring: Tufts University School of Medicine and TMC

International Infectious Disease Research and Mentoring: Tufts University School of Medicine and TMC International Infectious Disease Research and Mentoring: Tufts University School of Medicine and TMC Christine Wanke, MD Professor of Medicine and Public Health and Community Medicine Director, Division

More information

Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015

Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy

More information

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background

More information

CD4 T cell Enumeration in the Diagnosis and Management of Pediatric HIV infection

CD4 T cell Enumeration in the Diagnosis and Management of Pediatric HIV infection CD4 T cell Enumeration in the Diagnosis and Management of Pediatric HIV infection Maurice (Mo) R.G. O Gorman, Ph.D. Professor of Pathology and Pediatrics Keck School of Medicine, U. of Southern California

More information

Understanding the Immune System in Myeloma

Understanding the Immune System in Myeloma Brian GM Durie Understanding the Immune System in Myeloma Living Well with Myeloma Teleconference Series Thursday, March 19 th 2015 1 The Immune System is Like a Swiss Watch B Cell T Cell Plasma Cell Changing

More information

Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation

Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation ISPUB.COM The Internet Journal of Infectious Diseases Volume 6 Number 2 Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation Y Graza,

More information

EMA and Progressive Multifocal Leukoencephalopathy.

EMA and Progressive Multifocal Leukoencephalopathy. EMA and Progressive Multifocal Leukoencephalopathy. ENCePP Plenary, London 23 November 2011 Presented by: Henry Fitt Head of Coordination & Networking, Pharmacovigilance & Risk Management An agency of

More information

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in

More information

CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES

CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES CHAPTER 14 CELL SURFACE MARKERS OF T-CELLS, B-CELLS AND MACROPHAGES An understanding of the distinct families of molecules present on different cells of the immune system provides the tools for distinguishing

More information

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO

Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous

More information

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015 The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response

More information

Cost Comparison and Clinical Evaluation of a Blood Test for Tuberculosis (TB) in a Correctional Setting

Cost Comparison and Clinical Evaluation of a Blood Test for Tuberculosis (TB) in a Correctional Setting Cost Comparison and Clinical Evaluation of a Blood Test for Tuberculosis (TB) in a Correctional Setting Princess Adaku Iroh, M.Sc. Academic and Health Policy Conference on Correctional Health March 20th,

More information

IGRA guidelines. P. Van Bleyenbergh and Respiratory Infections Working Group

IGRA guidelines. P. Van Bleyenbergh and Respiratory Infections Working Group IGRA guidelines P. Van Bleyenbergh and Respiratory Infections Working Group Financial statement The speaker has no financial involvement with any organization or entity with a financial interest in the

More information

Chapter 43: The Immune System

Chapter 43: The Immune System Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2

More information

IGRAs: Yesterday, Today and Tomorrow

IGRAs: Yesterday, Today and Tomorrow Interferon Gamma Release Assays(IGRAs): Yesterday, Today and Tomorrow Grand Rounds Philip LoBue, MD, FACP, FCCP Associate Director for Science Division of Tuberculosis Elimination National Center for HIV/AIDS,

More information

Policy Directive: compliance is mandatory

Policy Directive: compliance is mandatory Policy Directive: compliance is mandatory Policy for Control of Tuberculosis in South Australian Health Services Policy developed by: Public Health and Clinical Coordination Approved at Portfolio Executive

More information

HIV Therapy Key Clinical Indicator (KCI)

HIV Therapy Key Clinical Indicator (KCI) Publication Report HIV Therapy Key Clinical Indicator (KCI) Year ending 31 December 2010 Publication date 27 September 2011 A National Statistics Publication for Scotland Contents Contents... 1 About ISD...

More information

Linda Beer, PhD and Jacek Skarbinski, MD for the Medical Monitoring Project

Linda Beer, PhD and Jacek Skarbinski, MD for the Medical Monitoring Project Adherence to Antiretroviral Therapy and Disparities in Viral Suppression among U.S. Black and White Men Who Have Sex With Men Medical Monitoring Project, 2009 Linda Beer, PhD and Jacek Skarbinski, MD for

More information

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG

TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG Tx CENTERS Tuberculosis Control Program Health and Human Services Agency San Diego County INTRODUCTION Reducing TB disease requires

More information

Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California

Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening

More information

Recent Advances in The Treatment of Mycobacterium Tuberculosis

Recent Advances in The Treatment of Mycobacterium Tuberculosis Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my

More information

San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection

San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection San Francisco Guidelines on the Use of QuantiFERON-TB Gold (In Tube Method) for the Diagnosis of Latent TB Infection Rationale When to Screen for TB Choosing the Right TB Test Patient Registration Pre-Test

More information

TB & TB Testing Frequently Asked Questions

TB & TB Testing Frequently Asked Questions TB & TB Testing Frequently Asked Questions 1. Why are there different measurements for the tuberculin skin test (TST)? a. The classification is based on the person s risk of being infected with TB and

More information

TB-HIV Co-Infection in Children. Reené Naidoo Paediatric HIV/TB Symposium August 2013

TB-HIV Co-Infection in Children. Reené Naidoo Paediatric HIV/TB Symposium August 2013 TB-HIV Co-Infection in Children Reené Naidoo Paediatric HIV/TB Symposium August 2013 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children in South Africa HIV infection

More information

CIBMTR Infection Data and the New Infection Inserts.

CIBMTR Infection Data and the New Infection Inserts. CIBMTR Infection Data and the New Infection Inserts. Marcie Tomblyn, MD, MS Scientific Director, CIBMTR Infection and Immune Reconstitution Working Committee Overview Indication for expanded data collection

More information

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit

MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section

More information

Viral load testing. medical monitoring: viral load testing: 1

Viral load testing. medical monitoring: viral load testing: 1 medical monitoring: viral load testing: 1 medical monitoring: viral load testing Viral load testing medical monitoring: viral load testing: 2 Slide 1 Viral load The viral load test measures HIV in the

More information

Chapter 1 Overview of Tuberculosis Epidemiology in the United States

Chapter 1 Overview of Tuberculosis Epidemiology in the United States Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United

More information

B Cells and Antibodies

B Cells and Antibodies B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production

More information

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Frequently Asked Questions

Frequently Asked Questions Frequently Asked Questions QuantiFERON -TB Gold Health Professionals www.quantiferon.com 2 FAQ - Health Professionals Table of contents About TB 6 What is latent TB? And how is it different from active

More information

11/20/2011. Outline. Immune System Function. Terminology. Two Types of Immune Defense. Innate Immunity = Non Specific

11/20/2011. Outline. Immune System Function. Terminology. Two Types of Immune Defense. Innate Immunity = Non Specific Chapter 43 Immune System Outline I. Nonspecific Defenses A. Barrier B. Protective proteins C. Phagocytes D. Natural killer cells E. Inflammatory reaction II. Specific Defenses A. B cells Antibody mediated

More information

Challenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department

Challenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department Challenges in Pediatric Tuberculosis Mimi Emig, MD Spectrum Health Kent County Health Department Pediatric Tuberculosis: A Missed Public Health Opportunity Mimi Emig, MD Spectrum Health Kent County Health

More information

Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort.

Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort. TUPE089 Virologic suppression outcomes of second-line antiretroviral therapy in a Nigerian cohort. Authors: Adedotun A. Adetunji 1, MBChB, MSc; Chad Achenbach 2, MD, MPH; Joseph Feinglass 3, PhD; Kristin

More information

Microbiology AN INTRODUCTION EIGHTH EDITION

Microbiology AN INTRODUCTION EIGHTH EDITION TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein

More information

Sub-Saharan Africa and the Indian Ocean

Sub-Saharan Africa and the Indian Ocean Region Institut Pasteur The Institut Pasteur International Network Sub-Saharan Africa and the Indian Ocean Science has no native land, it embraces all humankind. Louis Pasteur Sub-Saharan Africa and the

More information

Journée des Industriels du Réseau TRIGGERSEP

Journée des Industriels du Réseau TRIGGERSEP Journée des Industriels du Réseau TRIGGERSEP Djillali ANNANE Hôpital Raymond Poincaré (AP-HP) Lab Cell Death Inflamation & Infection UMR1173 UVSQ/INSERM Mercredi 3 juin 2015 Institut Pasteur Paris Expertise:

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: immune_cell_function_assay 11/2009 3/2016 3/2017 3/2016 Description of Procedure or Service Careful monitoring

More information

DIVISION of SUBSTANCE ABUSE SERVICES. Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs

DIVISION of SUBSTANCE ABUSE SERVICES. Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs DIVISION of SUBSTANCE ABUSE SERVICES Tuberculosis Control Guidelines for Alcohol and Drug Abuse Treatment Programs 1. Purpose: This policy provides guidance and instruction to identify and prevent tuberculosis

More information

7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology)

7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology) 7- Master s Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 38 credit hours: 1- Basic requirements: 10 credit hours. 150701, 150702, 150703,

More information

Paediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation

Paediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation Paediatrica Indonesiana VOLUME 51 November NUMBER 6 Original Article Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation Rina Triasih 1,2,

More information

Guidelines for the Diagnosis and Treatment of Primary Immune Deficiency

Guidelines for the Diagnosis and Treatment of Primary Immune Deficiency Guidelines for the Diagnosis and Treatment of Primary Immune Deficiency Bruce Mazer MD McGill University Health Center Montreal Children s Hospital Meakins Christie Laboratories National Consensus Canadian

More information

CME Article Hiv Disease Surveillance

CME Article Hiv Disease Surveillance CME Article Hiv Disease Surveillance hiv disease surveillance cme Collaboration between Medicine and Public Health Sindy M. Paul, md, mph; Helene Cross, phd; Linda Dimasi, mpa; Abdel R. Ibrahim, phd; and

More information

MM Thorell PhD University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, Pennsylvania, , USA.

MM Thorell PhD University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, Pennsylvania, , USA. Medical Journal of Therapeutics Africa 2007 Vol 1, No 2 Page 148 SUMMARY OF GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS. MM Thorell PhD University of the Sciences

More information

HIV Drug Resistance in the Asia- Pacific

HIV Drug Resistance in the Asia- Pacific HIV Drug Resistance in the Asia- Pacific David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia HIVDR in Asia Pacific Transmitted resistance

More information

Human Immunity. How our body s cells defend against microbial and viral invaders

Human Immunity. How our body s cells defend against microbial and viral invaders Human Immunity How our body s cells defend against microbial and viral invaders What is Immunity? The word immunity comes from the Latin immunus meaning free of burden. Thus; it is a body s general ability

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load

Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation. M Dinaker. Fig.1: Effect of CART on CD4 and viral load Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)

More information

PATHOGENESIS OF AIDS

PATHOGENESIS OF AIDS Neal Nathanson, MD Emeritus Professor Department of Microbiology University of Pennsylvania School of Medicine 1 Definitions Structure of HIV HIV entry and cell tropism HIV-cell interactions Course of

More information

QuantiFERON -TB Gold (QFT ) Tuberculosis Screening with QuantiFERON. Lunch and Learn. Cathy Yanda. Nancy Hyland

QuantiFERON -TB Gold (QFT ) Tuberculosis Screening with QuantiFERON. Lunch and Learn. Cathy Yanda. Nancy Hyland QuantiFERON -TB Gold (QFT ) Tuberculosis Screening with QuantiFERON Lunch and Learn Cathy Yanda Corrections Specialist, QuantiFERON 312-504-2942 Nancy Hyland Inside Sales, QFN West 661-702-3752 US QFT

More information

International Experiences in Developing the HIV Service Cascade. RESPOND Conference, June 2015 Shirley Ko, Health Advisor, Pact

International Experiences in Developing the HIV Service Cascade. RESPOND Conference, June 2015 Shirley Ko, Health Advisor, Pact International Experiences in Developing the HIV Service Cascade RESPOND Conference, June 2015 Shirley Ko, Health Advisor, Pact HIV Cascade of Care Model that outlines the sequential stages, or continuum,

More information

The Body s Defenses CHAPTER 24

The Body s Defenses CHAPTER 24 CHAPTER 24 The Body s Defenses PowerPoint Lectures for Essential Biology, Third Edition Neil Campbell, Jane Reece, and Eric Simon Essential Biology with Physiology, Second Edition Neil Campbell, Jane Reece,

More information

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1:

1 2 3 4 5 6 Figure 4.1: Gel picture showing Generation of HIV-1subtype C codon optimized env expressing recombinant plasmid pvax-1: Full-fledged work is in progress towards construction and cloning of codon optimized envelope with subsequent aims towards immunization of mice to study immune responses. 1 2 4 5 6 Figure 4.1: Gel picture

More information

Tuberculosis Exposures at Santa Clara Valley Medical Center

Tuberculosis Exposures at Santa Clara Valley Medical Center Tuberculosis Exposures at Santa Clara Valley Medical Center May 11, 2016 Objectives To provide basic definitions of tuberculosis including differentiation between active tuberculosis disease and latent

More information

Screen for TB with confidence

Screen for TB with confidence Screen for TB with confidence QuantiFERON -TB Gold Plus the most accurate test for TB infection Sample to Insight TB is a preventable disease Tuberculosis (TB) is a contagious and deadly disease that is

More information

X-Plain Pediatric Tuberculosis Reference Summary

X-Plain Pediatric Tuberculosis Reference Summary X-Plain Pediatric Tuberculosis Reference Summary Introduction Tuberculosis, or TB, is a bacterial infection that causes more deaths in the world than any other infectious disease. When a child gets TB,

More information

annex 2 country profiles

annex 2 country profiles Annex 2 Country profiles Afghanistan High TB burden Estimates of TB burden a 213 Rate (per 1 population) 13 (8.4 16) 42 (27 53) Mortality (HIV+TB only).82 (.65.1).27 (.21.33) (includes HIV+TB) 1 (54 17)

More information

Clinical Review HIV/AIDS. Clinical experience with QuantiFERON - TB Gold. Sample to Insight. This clinical guide was reviewed and edited by:

Clinical Review HIV/AIDS. Clinical experience with QuantiFERON - TB Gold. Sample to Insight. This clinical guide was reviewed and edited by: Clinical Review Clinical experience with QuantiFERON - TB Gold HIV/AIDS This clinical guide was reviewed and edited by: Michael Sension, MD Medical Director, HIV Clinical Research Broward Health Fort Lauderdale,

More information

Global Update on HIV Treatment 2013: Results, Impact and Opportunities

Global Update on HIV Treatment 2013: Results, Impact and Opportunities June 2013 Global Update on HIV Treatment 2013: Results, Impact and Opportunities WHO/UNAIDS/UNICEF v2 Outline Results: Progress towards Global Targets - Antiretroviral treatment - Prevention of mother-to-child

More information

The Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense

The Immune System. 2 Types of Defense Mechanisms. Lines of Defense. Line of Defense. Lines of Defense The Immune System 2 Types of Defense Mechanisms Immune System the system that fights infection by producing cells to inactivate foreign substances to avoid infection and disease. Immunity the body s ability

More information

Appendix E-- The CDC s Current and Proposed Classification System for HIV Infection

Appendix E-- The CDC s Current and Proposed Classification System for HIV Infection Appendix E-- The CDC s Current and Proposed Classification System for HIV Infection The Centers for Disease Control (CDC) has developed a classification system for human immunodeficiency virus (HIV) infection

More information

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group Evidence based recommendations on non-specific effects of BCG, DTP-containing and measles-containing vaccines on mortality in children under 5 years of age Background paper for SAGE discussions SAGE non-specific

More information

IGRAs: What do they tell and what don t they tell us?

IGRAs: What do they tell and what don t they tell us? IGRAs: What do they tell and what don t they tell us? 2 nd European Advanced Clinical Tuberculosis Course Monday 22 nd September 2014 Amsterdam, Netherlands Ibrahim Abubakar Professor of Infectious Disease

More information

Dr David Chadwick. James Cook University Hospital, Middlesbrough. 19 th Annual Conference of the British HIV Association (BHIVA)

Dr David Chadwick. James Cook University Hospital, Middlesbrough. 19 th Annual Conference of the British HIV Association (BHIVA) 19 th Annual Conference of the British HIV Association (BHIVA) Dr David Chadwick James Cook University Hospital, Middlesbrough 16-19 April 2013, Manchester Central Convention Complex Occult hepatitis B/HIV

More information